Calico / AbbVie collaboration announcement demonstrates growth of the Rejuvenation Biotechnology industry

Posted by Mike Kope, CEO on September 04, 2014 | Outreach

Reuter's announced today the launch of a Calico/Abbvie agreement ("Google's Calico, Abbvie forge deal against diseases of aging").

SENS Research Foundation congratulates U.S. drugmaker AbbVie Inc and Calico on the excellent news of their collaboration. Their shared investments will create much-needed research facilities and accelerate the discovery and development of new medicines. This collaboration creates an important new path to the clinical development of treatments for the debilitating and life-threatening diseases of aging.

Though the agreement does not announce their research priorities, our recent Rejuvenation Biotechnology Conference demonstrated the need for large pharmaceutical company commitment, and for an acknowledgment of potentially long timelines - and both are reflected here.   Most importantly, this investment reflects the increasing investor appreciation we have seen for the potential astronomical scale of a real anti-aging industry.